- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02247544
Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma (TRAVELL)
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
This is an Italian, multicentre, single arm, phase II study, with an intra-patient comparison end point. This study aims at confirming the activity of the drug trabectedin as second/further line treatment in retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma expressed in terms of slowing down tumour growth.
Another objective is to investigate this peculiar benefit of trabectedin in typical retroperitoneal sarcomas may be exploited to help multidisciplinary clinical decision-making in the management of retroperitoneal sarcomas
Study Overview
Detailed Description
Retroperitoneal soft-tissue sarcomas (R-STSs) are rare neoplasms, accounting for 10% to 15% of Soft Tissue Sarcomas (STSs), which represent 1-3% of all cancers. They may show different histological types, but the predominant ones in the retroperitoneal region are: leiomyosarcoma, liposarcoma. The most commonly encountered in the retroperitoneum is the well differentiated/dedifferentiated liposarcoma.
First-line chemotherapy usually consists of doxorubicin and/or ifosfamide. These two drugs are the most active agents in adult STSs, with a dose-response relationship and response rates between 20% and 50%. However, the sarcoma community is currently doubtful as to the activity of ifosfamide in the subgroup of leiomyosarcomas.
Trabectedin has been found to be mainly active in leiomyosarcoma and liposarcoma and is approved by European Medicines Agency (EMA) as second-line chemotherapy for STSs. Although the response rate observed in pre-registration studies did not exceed 10%, trabectedin provided disease control, with progression arrest rates exceeding 50% and Progression Free Survival (PFS) rates exceeding 20% at 6 months.
Since so far no phase II studies tested the activity of trabectedin in retroperitoneal sarcomas, this is the specific aim of this study.
Target population: Patients with previously treated, histologically confirmed, retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma. Patients may be either unamenable to surgery or amenable but in whom the addition of medical treatment is considered clinically advisable.
Translational studies will be performed, with the aim of characterising the tumour biological features associated with different response patterns to trabectedin. These assessments will be done in 15-20 patients who will undergo surgery after trabectedin, comparing tumour tissue specimens collected before and after treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Napoli, Italy, 80131
- Istituto Nazionale Tumori - IRCCS - Fondazione Pascale
-
-
BA
-
Bari, BA, Italy, 70124
- Istituto Tumori Giovanni Paolo II
-
-
BG
-
Bergamo, BG, Italy, 24127
- Azienda Ospedaliera Giovanni Paolo XXIII
-
-
BO
-
Bologna, BO, Italy, 40138
- Azienda Ospedaliera S. Orsola-Malpighi
-
-
BS
-
Brescia, BS, Italy, 25123
- A.O. Spedali Civili
-
-
CA
-
Cagliari, CA, Italy, 09122
- Ospedale Oncologico A. Businco
-
-
CN
-
Cuneo, CN, Italy, 12100
- Azienda Ospedaliera S Croce e Carle
-
-
CO
-
Como, CO, Italy, 22020
- Azienda Ospedaliera Sant'Anna
-
-
FC
-
Meldola, FC, Italy, 47014
- IRST IRCCS Meldola
-
-
MI
-
Milano, MI, Italy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milano, MI, Italy, 20141
- Istituto Europeo di Oncologia
-
Rozzano, MI, Italy, 20089
- Istituto Clinico Humanitas
-
-
PA
-
Palermo, PA, Italy, 90127
- Azienda ospedaliera universitaria paolo giaccone
-
-
PD
-
Aviano, PD, Italy, 33081
- Centro di Riferimento Oncologico di Aviano
-
Padova, PD, Italy, 35128
- Istituto Oncologico Veneto
-
-
PI
-
Pisa, PI, Italy, 56124
- Azienda Ospedaliera Universitaria Santa Chiara
-
-
PO
-
Prato, PO, Italy, 59100
- Ospedale Misericordia e Dolce
-
-
RM
-
Roma, RM, Italy, 00128
- Policlinico Universitario Campus Biomedico
-
-
TO
-
Candiolo, TO, Italy, 10060
- Istituto per la Ricerca e la Cura del Cancro di Candiolo
-
Torino, TO, Italy, 10153
- Ospedale Gradenigo
-
-
TR
-
Terni, TR, Italy, 05100
- Azienda Ospedaliera Santa Maria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Persistent or locally relapsed and/or metastatic disease (in case of local disease, surgery may be technically feasible or not, but the clinical judgment must be that medical therapy is indicated)
- Pathology specimens available for centralized review
- Age ≥ 18 years
- European Eastern Cooperative Oncology Group Personal Status (ECOG PS) ≤ 2
- One or more previous systemic treatments employing anthracyclines and ifosfamide (unless one or both are clinically contraindicated)
- Measurable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST)
- A minimum of 3 weeks since any previous medical therapy
- Recovery from toxic effects of prior therapies to National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade 1 or lower
- Adequate haematological, renal and liver functions
- Ability and willingness to provide informed consent
Exclusion Criteria:
- Pregnant or breast-feeding women
- Prior exposure to trabectedin
- Peripheral neuropathy, Grade 2 or higher
- History of other malignancies (except for basal cell carcinoma or cervical carcinoma in situ, adequately treated), unless in remission for 5 years or more and judged of negligible potential of relapse
- Known central nervous system (CNS) metastases
- Active viral hepatitis or chronic liver disease
- Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within one year before enrolment, uncontrolled arterial hypertension or arrhythmias
- Active major infection
- Other serious concomitant illnesses
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trabectedin
Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1). Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response. |
Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Growth Modulation Rate
Time Frame: From date of randomization until progressive disease, assessed up to 48 months
|
The primary end point of the study will be the proportion of responders to trabectedin, based on the ratio, in each single patient, between PFS under trabectedin (PFS) and time to progression after previous chemotherapy treatment (TTP1).
|
From date of randomization until progressive disease, assessed up to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response (OR) in the overall sample
Time Frame: From date of randomization until progressive disease, assessed up to 48 months
|
From date of randomization until progressive disease, assessed up to 48 months
|
|
Pathological tumour response in the two eligible histological types, in patients undergoing surgery after treatment
Time Frame: From date of randomization until the best tumour dimensional response, assessed up to 48 months
|
From date of randomization until the best tumour dimensional response, assessed up to 48 months
|
|
PFS and OR in the two eligible histological types
Time Frame: From date of randomization until progressive disease, assessed up to 48 months
|
From date of randomization until progressive disease, assessed up to 48 months
|
|
PFS in patients who undergo surgery after, or during, medical therapy and those who do not
Time Frame: From date of randomization until progressive disease, assessed up to 48 months
|
From date of randomization until progressive disease, assessed up to 48 months
|
|
Number of patients with grade>=3 adverse drug reactions, number of serious adverse events related to study drug and number of patients who will experience at least one serious adverse event
Time Frame: From date of randomization until progressive disease, assessed up to 48 months
|
From date of randomization until progressive disease, assessed up to 48 months
|
|
Efficacy of trabectedin in reducing cancer related pain
Time Frame: From date of randomization until progressive disease, assessed up to 48 months
|
All patients will be administered a standardized questionnaire evaluating cancer related pain and use of antalgic medication.
|
From date of randomization until progressive disease, assessed up to 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paolo G. Casali, MD, IRCCS Fondazione Istituto Nazionale per la cura dei tumori di Milano
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISG-STS-TRAB-2012
- 2012-005428-14 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leiomyosarcoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIC Uterine Corpus Leiomyosarcoma... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus LeiomyosarcomaUnited States, Puerto Rico
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedUterus Leiomyosarcoma | Soft Tissue LeiomyosarcomaFrance
-
National Cancer Institute (NCI)Active, not recruitingStage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Uterine Corpus LeiomyosarcomaUnited States
-
Kristen GanjooRecruitingUterine Leiomyosarcoma | LMS - LeiomyosarcomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Liposarcoma | Unresectable LiposarcomaUnited States
-
David Liebner, MDWithdrawnLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Stage III Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma AJCC v8United States
-
Gachon University Gil Medical CenterMerck KGaA, Darmstadt, Germany; Chong Kun Dang Pharmaceutical Corp.RecruitingLeiomyosarcoma MetastaticKorea, Republic of
Clinical Trials on Trabectedin
-
Italian Sarcoma GroupAstraZeneca; PharmaMarActive, not recruitingAdvanced Soft Tissue SarcomaItaly
-
Italian Sarcoma GroupPharmaMarWithdrawnLeiomyosarcoma | Liposarcoma | Synovial SarcomaItaly
-
PharmaMar, SpainCompletedSoft Tissue SarcomaGermany
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedSarcomaUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
-
European Organisation for Research and Treatment...CompletedUnspecified Adult Solid Tumor, Protocol SpecificFrance, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
-
University of Colorado, DenverWithdrawn
-
Grupo Español de Investigación en Cáncer de OvarioCompleted
-
Suriya YessentayevaJohnson & JohnsonUnknown